- Category: HIV Treatment
- Published on Tuesday, 29 January 2013 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week approved revised label information for Complera, Gilead Sciences' tenofovir/emtricitabine/rilpivirine single-tablet regimen. Among the changes, the updated label clarifies that this regimen is indicated for previously untreated people with low baseline viral load, as those with higher levels were more likely to experience treatment failure in clinical trials.